Aro Biotherapeutics Co
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2022 | $24 M | No. 4 | $10 to $50 million | equity, options | SEC | |
| Dec 2020 | $90 M | No. 3 | $50 to $250 million | equity | SEC | |
| Dec 2019 | $5 M | No. 2 | $2 to $10 million | debt, options | SEC | |
| Mar 2019 | $4 M | No. 1 | $2 to $10 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Aro Biotherapeutics Co chose not to state its revenue in its newest notice of a funding round (Dec 2022).
SEC Form D · Dec 2022
The industry group it chose in its notices: Biotechnology.
SEC Form D · Dec 2022
That is all the official record says: Aro Biotherapeutics Co has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Aro Biotherapeutics Co is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 14 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Karyn B O'Neil | Executive officer | Dec 2022 |
| Mark B Laurenzi | Executive officer | Dec 2022 |
| Mittie B Doyle | Executive officer | Dec 2022 |
| Scott B Greenberg | Executive officer | Dec 2022 |
| Susan B Dillon | Executive officer | Dec 2022 |
| Mark V. Laurenzi | Executive officer | Apr 2019 |
| Bruce B Peacock | Director | Dec 2022 |
| Christopher B Mirabelli | Director | Dec 2022 |
| Daniel B Janse | Director | Dec 2022 |
| Elizabeth B Anderson | Director | Dec 2022 |
| Karyn B O'Neil | Director | Dec 2022 |
| Kevin B Raidy | Director | Dec 2022 |
| Marten B Steen | Director | Dec 2022 |
| Susan B Dillon | Director | Dec 2022 |
| Jess B Lifton | Director | Dec 2021 |
| Saan-Chirag B Gandhi | Director | Jun 2021 |
| Bruce V. Peacock | Director | Apr 2019 |
| Elizabeth V. Anderson | Director | Apr 2019 |